Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill targets blood pressure that resists standard drugs

NCT ID NCT07833098

NEW Disease control Sponsor: Zhejiang Yangli Pharmaceutical Technology Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 22, 2026 · Last updated Sep 22, 2026

Summary

Researchers are testing an experimental oral drug called VB19055 in adults whose blood pressure remains high despite taking two or more antihypertensive medications. The Phase II trial enrolls 240 participants and assigns them at random to one of three doses of VB19055 or a placebo, all taken once daily for 12 weeks. Neither participants nor doctors know which treatment each person receives. The main goal is to measure changes in seated clinic systolic blood pressure from the start of the trial to week 12.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VB19055, an experimental oral blood pressure drug
What this could lead to
If VB19055 works, it could offer a new oral option for people whose blood pressure stays high despite taking two or more medications.
What could go wrong
This is a Phase II trial, so researchers still need to confirm whether VB19055 lowers blood pressure and whether it is safe. Many drugs fail at this stage, and the 12-week treatment period cannot show long-term benefits or risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult male and female aged ≥18 years; * Mean seated systolic blood pressure (SBP) ≥140 mmHg and \<170 mmHg at screening, and SBP ≥135 mmHg and \<170 mmHg at randomization (Mean seated SBP/DBP is defined as the average of 3 seated SBP/DBP measurements obtained by automated office blood pressure measurement at a single clinic visit. If the trial participant has not taken routine antihypertensive medication prior to the visit, a repeat mean blood pressure measurement may be performed within 2 days after dosing.) * Meet at least one of the following two criteria: 1. Uncontrolled hypertension: At screening and randomization, as judged by the investigator, stably taking antihypertensive medications of two different therapeutic classes at maximum tolerated dose for ≥4 weeks (at least one must be a non-potassium-sparing diuretic). Beta-blockers used for other indications (e.g., migraine, heart failure, coronary artery disease) shall not count toward antihypertensive medications for eligibility; 2. Resistant hypertension: At screening and randomization, as judged by the investigator, stably taking antihypertensive medications of ≥3 different therapeutic classes at maximum tolerated dose for ≥4 weeks (at least one must be a non-potassium-sparing diuretic). Beta-blockers used for other indications (e.g., migraine, heart failure, coronary artery disease) shall not count toward antihypertensive medications for eligibility. * Serum potassium (K⁺) ≥3.5 and \<5.0 mmol/L at screening (local laboratory); * Morning (08:00 ± 2 hours) serum cortisol \>3 µg/dL (local or central laboratory); * Female participants of childbearing potential agree to no pregnancy plans and use highly effective contraception from ICF signing until 30 days after last dose; male participants agree to no fertility plans and use highly effective contraception from ICF signing until 90 days after last dose (see Appendix 2 for details); * Voluntarily participate in this clinical study and have the capacity to sign the informed consent form. Exclusion Criteria: * Known causes of secondary hypertension: renal artery stenosis, uncontrolled or untreated hyperthyroidism/hypothyroidism, hyperparathyroidism, pheochromocytoma, Cushing's syndrome, aortic coarctation, or obstructive sleep apnea syndrome being treated with continuous positive airway pressure (CPAP) (participants with primary aldosteronism may be considered for enrollment unless adrenalectomy is planned before study completion); * Have undergone coronary revascularization (percutaneous coronary intervention \[PCI\] or coronary artery bypass grafting \[CABG\]) or any major surgery (e.g., valve replacement, peripheral artery bypass surgery) within 6 months prior to ICF signing, or plan to undergo such procedures during the study; * Arrhythmia requiring treatment or left bundle branch block at screening; * Known chronic permanent atrial fibrillation; * New York Heart Association (NYHA) Class III or IV chronic heart failure at screening; * Glycated hemoglobin (HbA1c) \>9.5% at screening; * Adrenal insufficiency diagnosed within 6 months prior to ICF signing; * Any of the following abnormal laboratory/physical examination findings at screening: 1. Serum sodium \<135 mmol/L; 2. Mean seated SBP ≥170 mmHg or mean seated DBP ≥110 mmHg; 3. Aspartate aminotransferase (AST) \>3.0 × upper limit of normal (ULN) and/or alanine aminotransferase (ALT) \>3.0 × ULN; 4. Total bilirubin \>2.0 × ULN, unless the participant has a history of Gilbert's syndrome; 5. Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m²; 6. Body mass index (BMI) \<18 kg/m² or ≥45 kg/m²; 7. Any of the following ECG abnormalities: heart rate \<45 bpm or \>110 bpm; QT interval corrected by Fridericia's formula (QTcF) \>470 ms; 8. Clinically significant abnormal chest imaging (chest X-ray or computed tomography \[CT\]) assessed by the investigator as posing a safety risk; 9. Positive hepatitis B surface antigen (HBsAg) with possible viral replication (positive HBV DNA) as judged by the investigator based on further testing, or positive anti-hepatitis C virus (HCV) antibody, or positive human immunodeficiency virus (HIV) antibody.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertensive disorder resistant hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension Resistant hypertension Uncontrolled hypertension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    24 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Hospital of Jining Medical University

    Jining, China

  • Chengdu Second People's Hospital

    Chengdu, China

  • China Resources WISCO General Hospital

    Wuhan, China

  • Daqing People's Hospital

    Daqing, China

  • Liaoning Provincial People's Hospital

    Shenyang, China

  • Panjin Liaohe Oilfield Gem Flower Hospital

    Panjin, China

  • Peking University People's Hospital

    Beijing, China

  • Qilu Hospital of Shandong University

    Shandong, China

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, China

  • Shanxi Cardiovascular Hospital

    Shaxi, China

  • Shengjing Hospital of China Medical University

    Shenyang, China

  • Suzhou Municipal Hospital of Anhui Province

    Suzhou, China

  • The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology

    Baotou, China

  • The First Affiliated Hospital of University of South China

    Hengyang, China

  • The First Hospital of Hebei Medical University

    Hebei, China

  • The First People's Hospital of Xinxiang

    Xinxiang, China

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, China

  • The Seventh People's Hospital of Zhengzhou City

    Zhengzhou, China

  • The Third Hospital of Changsha

    Changsha, China

  • The Third People's Hospital of Luoyang

    Luoyang, China

  • The Third Xiangya Hospital of Central South University

    Changsha, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China

  • Zhengzhou Central Hospital

    Zhengzhou, China

  • Zhongda Hospital, Southeast University

    Nanjing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.